WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
RGLS
REGULUS THERAPEUTICS INC
$158.43M$0.00-$29.21M-$30.04M-$1.58N/A-100.00%N/AN/A2024-05-16
DYN
DYNE THERAPEUTICS INC
$2.03B$0.00-$233.48M-$235.94M-$3.95N/AN/AN/AN/A2024-05-22
ANEB
ANEBULO PHARMACEUTICALS INC
$70.12M$0.00-$10.46M-$10.49M-$0.42N/AN/AN/AN/A2024-05-09
MYMD
MYMD PHARMACEUTICALS INC
$6.13M$0.00-$4.00M-$8.22M-$5.33N/A-100.00%N/AN/A2024-05-13
CADL
CANDEL THERAPEUTICS INC
$187.53M$0.00-$34.14M-$37.94M-$1.31N/AN/AN/AN/A2024-05-09
VERU
VERU INC
$185.90M$15.93M-$62.11M-$64.59M-$0.75-42.55%-4.11%N/AN/A2024-06-18
TELO
TELOMIR PHARMACEUTICALS INC
$203.27M$0.00-$11.43M-$13.07M-$0.48N/AN/AN/AN/A
KPRX
KIORA PHARMACEUTICALS INC
$12.34M$0.00-$12.35M-$13.04M-$2.69N/A-100.00%N/AN/A2024-05-07
CVM
CEL SCI CORP
$72.15M$0.00-$26.34M-$31.05M-$0.69N/A-100.00%N/AN/A2024-05-10
PRME
PRIME MEDICINE INC
$530.73M$0.00-$180.97M-$198.13M-$2.18N/AN/AN/AN/A2024-05-09
BPTH
BIO-PATH HOLDINGS INC
$1.82M$0.00-$15.90M-$16.08M-$33.63N/AN/AN/AN/A2024-05-10
MLEC
MOOLEC SCIENCE SA
$54.47M$2.90M-$6.25M-$6.48M-$0.13N/AN/AN/AN/A2024-05-29
RENB
RENOVARO INC
$219.81M$0.00-$40.26M-$41.23M-$0.70N/AN/AN/AN/A2024-05-10
ERNA
ETERNA THERAPEUTICS INC
$9.68M$68.00k-$19.93M-$21.68M-$4.08N/A-68.89%N/AN/A2024-06-14
ABVC
ABVC BIOPHARMA INC
$15.00M$152.43k-$7.74M-$10.52M-$2.43-84.28%N/AN/AN/A2024-05-13
AEON
AEON BIOPHARMA INC
$191.59M$0.00$24.09M$24.05M$0.65N/AN/AN/AN/A
SER
SERINA THERAPEUTICS INC
$22.98M$142.00k-$9.77M-$14.80M-$13.72317.65%-36.69%N/AN/A2024-05-13
EFTR
EFFECTOR THERAPEUTICS INC
$6.97M$0.00-$32.78M-$35.81M-$16.37-100.00%N/AN/AN/A2024-05-07
KA
KINETA INC
$6.69M$5.44M-$13.01M-$14.10M-$1.28178.65%13.89%N/AN/A2024-06-06
CRBP
CORBUS PHARMACEUTICALS HOLDINGS INC
$359.39M$0.00-$41.04M-$44.60M-$10.31N/A-100.00%N/AN/A2024-05-16
NVAX
NOVAVAX INC
$572.41M$983.71M-$487.39M-$545.06M-$5.41-50.36%95.68%N/AN/A2024-05-07
CSBR
CHAMPIONS ONCOLOGY INC
$68.24M$49.22M-$7.67M-$9.73M-$0.72-8.29%15.19%N/AN/A
PSTV
PLUS THERAPEUTICS INC
$7.23M$4.91M-$12.18M-$13.32M-$4.242,093.30%10.49%N/AN/A2024-04-29
ASLN
ASLAN PHARMACEUTICALS LTD
$7.30M$12.00M-$39.41M-$44.22M-$2.75N/AN/AN/AN/A2024-04-29
JAGX
JAGUAR HEALTH INC
$49.72M$9.76M-$32.53M-$41.30M-$1.79-18.36%17.19%N/AN/A2024-05-13
ARMP
ARMATA PHARMACEUTICALS INC
$99.77M$4.53M-$65.45M-$69.05M-$1.91-17.77%N/AN/AN/A2024-06-12
ATRA
ATARA BIOTHERAPEUTICS INC
$82.36M$8.57M-$254.20M-$276.13M-$2.61-86.51%N/AN/AN/A2024-06-10
DRMA
DERMATA THERAPEUTICS INC
$2.28M$0.00-$7.79M-$7.79M-$2.67N/AN/AN/AN/A2024-05-16
ACXP
ACURX PHARMACEUTICALS INC
$32.62M$0.00-$14.58M-$14.58M-$1.15N/AN/AN/AN/A2024-06-14
HUMA
HUMACYTE INC
$475.14M$0.00-$96.41M-$110.78M-$1.07-100.00%N/AN/AN/A2024-06-06
ELTX
ELICIO THERAPEUTICS INC
$92.02M$0.00-$32.97M-$35.20M-$6.96N/A-100.00%N/AN/A2024-05-08
MAIA
MAIA BIOTECHNOLOGY INC
$58.81M$0.00-$19.77M-$19.77M-$1.49N/AN/AN/AN/A2024-05-06
HCWB
HCW BIOLOGICS INC
$52.95M$560.36k-$23.58M-$24.99M-$0.70-78.33%N/AN/AN/A2024-05-09
ICCC
IMMUCELL CORP
$39.84M$17.47M-$3.05M-$5.77M-$0.75-5.90%9.72%N/AN/A2024-06-14
GRTX
GALERA THERAPEUTICS INC
$10.12M$0.00-$47.41M-$59.08M-$1.33N/AN/AN/AN/A2024-06-13
RANI
RANI THERAPEUTICS HOLDINGS INC
$335.05M$0.00-$27.02M-$33.97M-$1.33N/AN/AN/AN/A2024-05-29
IBIO
IBIO INC
$6.13M$50.00k-$25.95M-$27.28M-$15.02-97.22%-43.46%N/AN/A2024-05-13
ENGN
ENGENE HOLDINGS INC
$675.51MN/AN/AN/AN/AN/AN/AN/AN/A
ZVSA
ZYVERSA THERAPEUTICS INC
$3.79M$0.00-$107.74M-$106.25M-$1.09kN/AN/AN/AN/A
YS
YS BIOPHARMA CO LTD
$74.45MN/AN/AN/AN/AN/AN/AN/AN/A
EPRX
EUPRAXIA PHARMACEUTICALS INC
N/A$0.00-$27.60M-$28.97M-$1.17N/AN/AN/AN/A2024-06-06
NRSN
NEUROSENSE THERAPEUTICS LTD
$18.92M$0.00-$8.97M-$11.28M-$0.83N/AN/AN/AN/A2024-05-25
CHRO
CHROMOCELL THERAPEUTICS CORP
$9.40M$0.00-$6.86M-$7.38M-$5.78N/AN/AN/AN/A
APTO
APTOSE BIOSCIENCES INC
$19.18M$0.00-$50.74M-$51.21M-$7.58N/AN/AN/AN/A2024-05-28
AKTX
AKARI THERAPEUTICS PLC
$18.78M$0.00-$10.00M-$10.01M$0.00N/AN/AN/AN/A2024-04-29
OTLK
OUTLOOK THERAPEUTICS INC
$109.70M$0.00-$52.51M-$51.50M-$4.00N/A-100.00%N/AN/A2024-05-13
ACHV
ACHIEVE LIFE SCIENCES INC
$157.90M$0.00-$26.73M-$29.82M-$1.50N/AN/AN/AN/A2024-06-06
BCLI
BRAINSTORM CELL THERAPEUTICS INC
$36.49M$0.00-$16.48M-$17.19M-$0.40N/AN/AN/AN/A2024-05-13
QLGN
QUALIGEN THERAPEUTICS INC
$1.83M$0.00-$11.89M-$13.42M-$2.65N/AN/AN/AN/A2024-05-14
CING
CINGULATE INC
$4.41M$0.00-$22.18M-$23.53M-$26.00N/AN/AN/AN/A
CNSP
CNS PHARMACEUTICALS INC
$2.29M$0.00-$18.83M-$18.85M-$5.00N/AN/AN/AN/A2024-05-13
SKYE
SKYE BIOSCIENCE INC
N/A$0.00-$36.61M-$37.64M-$5.37N/AN/AN/AN/A2024-06-05
VCNX
VACCINEX INC
$7.18M$570.00k-$20.13M-$20.25M-$43.68107.27%-4.67%N/AN/A2024-05-13
CLRB
CELLECTAR BIOSCIENCES INC
$97.75M$0.00-$37.79M-$37.98M-$3.11N/AN/AN/AN/A2024-06-21
SLS
SELLAS LIFE SCIENCES GROUP INC
$82.15M$0.00-$36.85M-$37.34M-$1.34-100.00%N/AN/AN/A2024-06-19
ALLR
ALLARITY THERAPEUTICS INC
$451.06k$0.00-$11.28M-$20.42M-$205.20N/AN/AN/AN/A
NRXP
NRX PHARMACEUTICALS INC
$33.88M$0.00-$30.03M-$30.16M-$4.00N/AN/AN/AN/A2024-05-14
ENSC
ENSYSCE BIOSCIENCES INC
$4.28M$0.00-$10.26M-$10.63M-$4.69N/AN/AN/AN/A2024-05-13
UNCY
UNICYCIVE THERAPEUTICS INC
$35.80M$0.00-$30.18M-$31.41M-$1.28N/AN/AN/AN/A2024-05-09
PTN
PALATIN TECHNOLOGIES INC
$29.37M$7.10M-$31.25M-$31.59M-$2.61146.20%-24.85%N/AN/A2024-06-19
ALZN
ALZAMEND NEURO INC
$4.94M$0.00-$12.35M-$12.40M-$1.87N/AN/AN/AN/A
IVA
INVENTIVA SA
$169.38M$25.18M-$109.06M-$120.03M-$2.6428.59%24.86%N/AN/A2024-05-29
GALT
GALECTIN THERAPEUTICS INC
$213.57M$0.00-$41.86M-$44.81M-$0.74N/AN/AN/AN/A2024-05-13
SCNI
SCINAI IMMUNOTHERAPEUTICS LTD
$2.00M$0.00N/A-$10.95M-$4.94N/AN/AN/AN/A
ANVS
ANNOVIS BIO INC
$198.31M$0.00-$56.20M-$56.20M-$6.23N/AN/AN/AN/A2024-06-14
RVPH
REVIVA PHARMACEUTICALS HOLDINGS INC
$83.48M$0.00-$39.24M-$39.26M-$1.65N/AN/AN/AN/A2024-05-13
VTVT
VTV THERAPEUTICS INC
$81.17M$0.00-$20.15M-$20.25M-$9.71-100.00%-100.00%N/AN/A2024-06-11
KTRA
KINTARA THERAPEUTICS INC
$5.82M$0.00-$10.58M-$10.77M-$5.96N/AN/AN/AN/A2024-05-09
OKYO
OKYO PHARMA LTD
$37.56M$0.00-$13.18M-$13.27M-$0.61N/AN/AN/AN/A2024-05-02
RNXT
RENOVORX INC
$20.96M$0.00-$10.12M-$10.23M-$0.99N/AN/AN/AN/A2024-06-07
BCTX
BRIACELL THERAPEUTICS CORP
$34.68M$0.00-$17.21M-$12.65M-$0.80N/AN/AN/AN/A2024-06-10
ATNF
180 LIFE SCIENCES CORP
$1.53M$0.00-$22.13M-$19.94M-$52.59N/AN/AN/AN/A2024-05-13
CDT
CONDUIT PHARMACEUTICALS INC
$234.04M$0.00-$324.00k-$535.00k-$0.01N/AN/AN/AN/A
ONCO
ONCONETIX INC
$2.61M$58.47k-$36.71M-$37.41M-$2.19N/AN/AN/AN/A2024-05-30
ICU
SEASTAR MEDICAL HOLDING CORP
$33.18M$0.00-$25.15M-$26.23M-$1.21N/AN/AN/AN/A2024-05-14
INKT
MINK THERAPEUTICS INC
$32.17M$0.00-$22.25M-$22.46M-$0.65N/AN/AN/AN/A2024-06-12
NLSP
NLS PHARMACEUTICS LTD
$4.89M$0.00-$15.36M-$15.47M-$0.50N/AN/AN/AN/A
PBM
PSYENCE BIOMEDICAL LTD
$11.50M$0.00$1.52M$1.52M-$0.01N/AN/AN/AN/A
OCEA
OCEAN BIOMEDICAL INC
$45.76M$0.00-$97.33M-$98.59M-$3.91N/AN/AN/AN/A
TVGN
TEVOGEN BIO HOLDINGS INC
$153.25M$0.00-$78.35M-$80.68M-$3.21N/AN/AN/AN/A
NKGN
NKGEN BIOTECH INC
$36.72M$0.00-$80.64M-$82.95M-$5.38-100.00%N/AN/AN/A
CLDI
CALIDI BIOTHERAPEUTICS INC
$5.72M$0.00-$26.88M-$29.22M-$1.73-100.00%N/AN/AN/A2024-05-29

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -29.72% over the past year, underperforming other biotech stocks by -8 percentage points.

Incyte has an average 1 year price target of $74.69, an upside of 44.53% from Incyte's current stock price of $51.68.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 23.08% have issued a Strong Buy rating, 23.08% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -7.45% over the past year, overperforming other biotech stocks by 15 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 27.33% from Harmony Biosciences Holdings's current stock price of $29.32.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 2.42% over the past year, overperforming other biotech stocks by 25 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 169.03% from Voyager Therapeutics's current stock price of $7.62.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 15.1%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 57.38%, which is 42 percentage points higher than the biotech industry average of 15.1%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.08%, which is -14 percentage points lower than the biotech industry average of 15.1%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.2% in the last day, and up 1.13% over the last week. Biodexa Pharmaceuticals was the among the top gainers in the biotechnology industry, gaining 79.31% yesterday.

Biodexa shares are trading higher after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 2.42% in the past year. It has overperformed other stocks in the biotech industry by 25 percentage points.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -20.21% in the past year. It has overperformed other stocks in the biotech industry by 2 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 72 points higher than the biotech industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -29.72% in the past year. It has underperformed other stocks in the biotech industry by -8 percentage points.

Are biotech stocks a good buy now?

49.23% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 91.76% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 14.88x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.